Answers are grounded in this paper and cite their sources.
THE ISSUE Although the United States is in the midst of the COVID-19 pandemic, it should not be forgotten that as a country, we are also experiencing a sexually transmitted disease (STD) epidemic.1 Two of these STDs, gonorrhea and chlamydia, are increasing at alarming rates, posing a major public health concern.1 The related risks for long-term health complications from these infections, especially when untreated, are widely established. In women, gonorrhea and chlamydia can spread into the uterus or fallopian tubes, causing pelvic inflammatory disease. It can also have other deleterious reproductive health complications including an increased risk of ectopic pregnancy, acquisition of human immunodeficiency virus, chronic pelvic pain, and, in some cases, infertility.2,3 In men, untreated infection can lead to urethritis, epididymitis, proctitis, Reiter syndrome, and, in rare cases, infertility.2,3 According to the Centers for Disease Control and Prevention's (CDC) report in 2018, STD rates have been growing in the United States at staggering rates, with 19% and 63% increases in chlamydia and gonorrhea infections, respectively, since 2014.4 There was a total of 1,758,668 reported cases of chlamydia and 583,405 cases of gonorrhea in the United States as of 2018.4 In addition, the estimated direct medical costs of chlamydia and gonorrhea in the United States in 2008 were $516.7 million and $162.1 million, respectively, in 2008.5 Strategies to treat patients who are diagnosed with STDs and their partners are essential in combating the rising rates of transmission, infection, and reinfection. Expedited partner therapy (EPT), which has been recommended in select circumstances by the CDC since 2006, is the clinical practice of providers treating the sex partners of patients diagnosed with gonorrhea or chlamydia without clinical assessment of the partner. Expedited partner therapy can be used for heterosexual contacts of patients with gonorrhea and chlamydia in whom clinical evaluation is unlikely.6 Many organizations have published position statements in support of EPT and its legalization, including the American Medical Association,6 the American Osteopathic Association,7 the American Bar Association,8 the American Academy of Family Physicians,9 the Society for Adolescent Medicine,10 and the American College of Obstetricians and Gynecologists.11 Greater implementation of EPT may be one way to reduce the rising rates of gonorrhea and chlamydia in this country. This article is a commentary that offers a brief overview of EPT in the United States and proposes recommendations to address potential challenges to its implementation, although other more comprehensive reviews of EPT are available. COST AND OVERALL EFFECTIVENESS Of EPT There is strong evidence suggesting that EPT is highly effective. A meta-analysis of randomized controlled trials found EPT use led to a decrease in the reinfection rate by 21% to 29% for gonorrhea and chlamydia, depending on the demographics of the index patient.12 Another study suggested that a lack of EPT legislation is associated with an increase in STD rates.13 Notably, not only does EPT improve health outcomes for patients, it is also cost-saving for health care systems. Expedited partner therapy is cost-saving because at baseline it is more effective at treating partners, resulting in fewer quality-adjusted life-years.14 The overall health care system costs for EPT compared with unassisted standard partner referral (SR) were 10% lower for index men and 8% lower for index women.14 Expedited partner therapy was also less costly per infected individual treated, $82 for EPT versus $137 for SR, including averted sequelae costs in the analysis.15 One important caveat is that the cost-effectiveness of EPT is only if the partner and the index user have the same insurance provider.14 However, taken together, this evidence suggests that EPT is an effective way to improve health outcomes for patients with STDs. EPT AND HEALTH CARE EQUITY Unassisted SR is the typical alternative to EPT in the United States, in which STD patients are counseled to refer their partners for examination and treatment. There are barriers to this standard practice. Stigma affects STD screening and treatment, possibly limiting a patients' partner's willingness to obtain appropriate care.16 Sexually transmitted diseases have been found to disproportionately impact communities of color including African Americans, American Indians/Alaskan Natives, and Hispanics.17 Also, groups of low socioeconomic status who may lack proper health insurance and have low health literacy have been found to be at high risk for STDs.17 Expedited partner therapy has the potential to turn this tide, providing greater treatment availability to these vulnerable populations and decreasing cost of care for both the state health care system and the patient. Expedited partner therapy clinicians can provide STD-diagnosed patients with medication or a prescription to deliver to their partner(s) as treatment for exposure. Expedited partner therapy is a unique opportunity to connect these stigmatized populations with proper care. Providers should inform any patient diagnosed with a gonorrhea and chlamydia with information about EPT to ensure that all patients are aware of this practice. CHALLENGES TO THE IMPLEMENTATION OF EPT The implementation of EPT is largely governed by state, not national, law. Expedited partner therapy is permissible in 45 states, is "potentially allowable" in 4 states including Alabama, Kansas, Oklahoma, South Dakota, and is currently prohibited in South Carolina (SC).18 Past studies have shown that EPT laws and policies were associated with higher reports of receipt of EPT among patients; thus, EPT should be legalized in SC to eliminate this barrier.19 In response to the continued STD epidemic in SC, the SC Board of Examiners has issued an updated position statement to allow for the use of EPT. However, even when the legality of EPT is not a major concern, there are many other implementation challenges that need to be addressed. One primary barrier to the use of EPT is a lack of knowledge about its availability by providers.20 Sexually transmitted disease programs should implement provider outreach and education to ensure that providers are aware of the legality and effectiveness of EPT. Outreach should be targeted especially toward providers treating sexual health areas of high spread. Also, training during residency could be implemented to ensure that future providers are aware of this treatment option. Providers should be prepared to discuss the practice with their patients who are undergoing the treatment of an STD, by having EPT-specific patient and partner fact sheets readily available.21 Another concern with the use of EPT is that a physician should physically examine a patient to make an informed medical judgment on whether or not to prescribe a prescription. However, although treating individuals without a physical examination is typically deemed unconventional, it is not completely unheard of. In many cases, physicians provide prescription medication to children or elderly patients through the proxy of a parent or caregiver. Each year, flu vaccines are also given to individuals who request it without physical evaluation of the patient. Although these examples are quite different from EPT, they share a common objective—ensuring that safe and effective medications are available to people who need them.22 Physicians often worry about the potential liability and malpractice issues that may ensue for harms incurred by the sex partners of index patients. However, past research has not found any reported cases in which courts have specifically addressed the liability of physicians, pharmacists, or other health care practitioners for partner injuries through the practice of EPT.23 To address these concerns, many states have implemented specific language on liability in legislation to protect providers. Partner treatment is also limited by the effort and cost of filling an EPT prescription by partners. It can be expensive to fill the prescription, particularly if the patient is uninsured. In one study, it was found that less than half of the prescriptions for EPT are filled.24 To address this challenge, health departments could purchase medication for EPT at discounted rates and then distribute these medications to medical providers who work with particularly vulnerable populations in areas of high spread. This is similar to how vaccines are distributed, and this could enable a system of publicly funded EPT.25 In addition, another challenge is that pharmacies or electronic health record systems may not be capable of supporting the use of EPT.21 It is essential that health departments and health care organizations work together to eliminate any logistical barriers that currently limit the provider's ability to offer their patients EPT. It is also important to note that there have been increasing antimicrobial-resistant gonorrhea strains. As a result, there has been a shift to ceftriaxone, an injection, as the preferred medication for gonorrhea treatment.26 This change in medication may present a challenge to the widespread use of EPT. CALL TO ACTION Expedited partner therapy may not offer a complete solution to the United States' growing chlamydia and gonorrhea rates, but it is a partial and viable solution to combat this issue. Because COVID-19 has resulted in the closure of many clinics and there is limited access to STD treatment,27 it is essential now more than ever to use EPT to offer a solution to combat the rising rates of gonorrhea and chlamydia. Official CDC recommendations for combatting the rising STD rates during the COVID-19 pandemic have highlighted the use of EPT.28 It is especially beneficial to high-risk populations who may not have access to adequate health care or desire to pursue a physical examination. In addition, as telehealth continues to grow during the COVID-19 pandemic and beyond, further research will be necessary to understand how telemedicine will influence EPT use. It is time for a call to action. Training programs for providers, nurses, nurse practitioners, and other key stakeholders need to be implemented to increase awareness of this now effective, evidence-based practice. Research should be conducted to further understand current provider practices and improve the implementation of EPT. Insurance companies need to start paying for the medications used in EPT, and health departments and clinics should work to eliminate logistical and financial barriers in the use of EPT. Patient education about the practice by providers is necessary to reduce many of the barriers to EPT use. As the threat of antibiotic-resistant strains increases, it is important to treat as many infected patients now and prevent further spread of disease.26 It is time for health care departments and providers nationwide to ensure widespread use of EPT to address the worsening STD epidemic in this country.
No takes yet. Share an insight, caveat, or question.
Nelson et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: